Publication | Closed Access

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Unrelated DonorsAnti-thymocyte GlobulinTransplantationMarrow TransplantationHematologyImmunologyAutoimmunityGraft SurvivalBlood TransplantationImmunotherapyMedicineCell TransplantationGraft RejectionPhase 3